


| Key | % Net Assets |
|---|---|
| 4.6% | |
| 4.5% | |
| 4.3% | |
| 4.3% | |
| 82.3% |
| Name | % Net Assets |
|---|---|
| Astrazeneca | 4.6% |
| GlaxoSmithKline | 4.5% |
| Smiths Group | 4.3% |
| Logica | 4.3% |
| Carnival | 4.2% |
| Imperial Tobacco Group | 4.1% |
| BT Group | 4.1% |
| Bunzl | 4.0% |
| Unilever | 4.0% |
| BG Group | 4.0% |
No asset data available.
| Date | 18-Mar-2022 |
|---|---|
| NAV | 304.48p |
| Currency | GBP |
| Change | 4.34p |
| % | 1.45% |
| YTD change | 304.48p |
| YTD % | n/a |
| Fund Inception | 05/11/2001 |
|---|---|
| Fund Manager | Marvyn Douglas |
| TER | 0.78 (31-Jan-2012) |
| Minimum Investment | |
|---|---|
| Initial | £500000 |
| Additional | n/a |
| Savings | n/a |
| Charges | |
|---|---|
| Initial | n/a |
| Annual Mang't | 0.70% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.02 |
| Sharpe ratio | 0.20 |
You are here: research